Skip to content

Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study.

Piha-Paul SA1, Taylor MH2, Spitz D3, Schwartzberg L4, Beck JT5, Bauer TM6, Meric-Bernstam F1, Purkayastha D7, Karpiak L7, Szpakowski S8, Braiteh F9

https://www.ncbi.nlm.nih.gov/pubmed/31741715